Trials
16 active
17 in total · 9 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- Colorectal Cancer (4 trials), Renal Cell Carcinoma (3 trials), Cancer (2 trials), Renal Cell Carcinoma (RCC) (2 trials), Hepatocellular Carcinoma (HCC) (2 trials), Non-Clear Cell Renal Cell Carcinoma (nccRCC) (2 trials), Solid Tumor (2 trials), Non-Clear Cell Renal Cell Carcinoma and 26 more
- Main trialPhase 3
- “The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.”In the company’s words, NCT05425940 on ClinicalTrials.gov
- Other names
- XL092
Other drugs for Colorectal Cancer
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up12
- 15 DecPhase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 May 2027Phase 1 trial completes · ClinicalTrials.gov
- 29 Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- 15 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 31 Jul 2028Phase 1 trial completes · ClinicalTrials.gov
- Aug 2028Phase 2/3 trial completes · ClinicalTrials.gov
- 30 Jun 2029Phase 2/3 trial completes · ClinicalTrials.gov
- 5 Apr 2030Phase 3 trial completes · ClinicalTrials.gov
- 31 May 2030Phase 3 trial completes · ClinicalTrials.gov
- 27 Nov 2030Phase 3 trial completes · ClinicalTrials.gov
- 26 Oct 2031Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07845786
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 16 Jun 2026 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | |
| Phase 3Active, not recruiting | 15 Dec 2026 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | |
| Phase 3Recruiting | 5 Apr 2030 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease | |
| Phase 3Enrolling by invitation | 31 May 2030 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | |
| Phase 3Recruiting | 27 Nov 2030 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | |
| Phase 3Recruiting | 27 Feb 2032 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) | |
| Phase 2/3Active, not recruiting | Aug 2028 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | |
| Phase 2/3Recruiting | 30 Jun 2029 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | |
| Phase 2Recruiting | 29 Feb 2028 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | |
| Phase 2Recruiting | 15 Jun 2028 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | |
| Phase 1/2Recruiting | 26 Oct 2031 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) | |
| Phase 1Recruiting | Dec 2025 | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) | |
| Phase 1Active, not recruiting | 31 Aug 2026 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | |
| Phase 1Recruiting | 31 Jan 2027 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | |
| Phase 1Recruiting | 31 May 2027 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | |
| Phase 1Not yet recruiting | 31 Jul 2028 | Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors | |
| Phase 1Terminated | 12 May 2025 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026